文献速递乳腺癌

BRCA1/2致病性变异携带者行或不行风险降低性乳房切除术的生存结局

Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers.
PubMed 文献 · J Clin Oncol · 2026-02-04

该前瞻性队列研究纳入460例选择双侧风险降低性乳房切除术(BRRM)和745例选择影像监测的BRCA1/2致病性变异携带者,比较总生存、乳腺癌特异性死亡和乳腺癌发病率。

要点

  • BRRM显著降低乳腺癌发病率,年发病率从2.4%降至0.15%。
  • BRRM与影像监测的乳腺癌特异性死亡和总生存无显著差异。
  • 选择影像监测的女性乳腺癌特异性生存和总生存 unlikely 受损。

核心结论

  • BRRM显著降低BRCA1/2致病性变异携带者的乳腺癌发病率,但未显著改善乳腺癌特异性死亡或总生存。

研究设计与样本

  • 前瞻性队列研究,纳入区域家族史/遗传服务中接受BRCA1/2基因检测的携带者。

主要发现

  • BRRM时诊断9例隐匿性癌(2%)。
  • 两组中乳腺癌死亡比例与卵巢癌死亡比例相似。

临床怎么用

  • 对于选择影像监测而非风险降低性手术的BRCA1/2携带者,可告知其乳腺癌特异性生存和总生存不太可能受损。
  • BRRM可显著降低乳腺癌发病率,该信息可用于支持BRCA1/2携带者的决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Many women carrying pathogenic variants (pvs) of BRCA1 and BRCA2 genes (pvBRCA1/2) elect to undergo bilateral risk-reducing mastectomy (BRRM) in the belief that it will improve their overall survival (OS). Although many are satisfied with their decision to undergo BRRM a significant minority exhibit regret. We compared long-term oncology outcomes in women with pvBRCA1/2 choosing BRRM with those choosing a program of imaging surveillance. METHODS: All participants were attendees at a regional family history/genetics service and had undergone genetic testing for pvBRCA1/2. Carriers of pvBRCA1/2 elected either to undergo BRRM or imaging surveillance as directed by UK national guidance. A prospective cohort design examined OS, breast cancer-specific death, and breast cancer incidence between the study groups. RESULTS: A total of 460 women elected to undergo BRRM, while 745 chose surveillance (median age, 37.2 years and 38.5 years, respectively; P = .06). Follow-up totaled 4,652 woman-years after BRRM. Overall annual incidence rate of breast cancer was 2.4%, falling to 0.15% after BRRM, a 94% reduction compared with surveillance alone (log-rank chi-square = 86.1; P < .001). There were nine occult cancers diagnosed at BRRM (2%). Breast cancer-specific deaths were similar in the BRRM and surveillance groups (two and four deaths, respectively; P = .36; 4,634 and 5,419 woman-years of follow-up, respectively). Proportionately, deaths from breast cancer were similar to deaths from ovarian cancer in both treatment groups. CONCLUSION: For women electing imaging surveillance over risk-reducing surgery, our results may offer reassurance that their breast cancer-specific survival and OS are unlikely to be compromised. However, breast cancer incidence rates are significantly reduced after BRRM compared with imaging surveillance, which may be important information for women with pvBRCA1/2 considering BRRM.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gandhi A, Howell SJ, Harkness EF, et al. Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers. J Clin Oncol. 2026. PMID: 41637687. doi:10.1200/JCO-25-00834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。